The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
TCT 2021 | Relationship between IL-15 serum concentrations & CD19 CAR T-cell therapy
Jordan Gauthier, MD, MSc, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the relationship between interleukin-15 (IL-15) serum concentrations, anti-tumor efficacy, and in vivo CAR T-cell kinetics in patients treated with anti-CD19 CAR T-cell therapies. IL-15 serum concentrations are associated with higher probabilities of response and higher CAR T-cell in vivo expansion and persistence. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
Disclosures
Consulting: JMP, Eusapharma, Multerra Bio
